Plasma level of soluble c-Met is tightly associated with the clinical risk of preeclampsia

Am J Obstet Gynecol. 2009 Dec;201(6):618.e1-7. doi: 10.1016/j.ajog.2009.07.032. Epub 2009 Sep 20.


Objective: The objective of the study was to examine the relevance of the soluble form c-Met (sMet) with the clinical risk for severe preeclampsia.

Study design: This prospective case-control study was performed by using plasma derived from 44 preeclamptic and 51 uncomplicated pregnant women. Plasma concentration of sMet was measured with specific enzyme-linked immunosorbent assay, and the predictive values were determined based on the receiver-operating characteristic (ROC) curves analysis.

Results: Plasma s-Met level in normal pregnant women changed in a gestation-dependent manner, peaking at weeks 19-24. In women with severe preeclampsia, the circulating sMet level was significantly lower than that in the gestational stage-matched controls during gestational weeks 15-30. The ROC curve analysis revealed a significant correlation between plasma sMet level and the risk of developing severe preeclampsia.

Conclusion: Plasma sMet could serve as a potential biomarker for predicting severe preeclampia at early second trimester of pregnancy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Case-Control Studies
  • Female
  • Humans
  • Pre-Eclampsia / blood*
  • Predictive Value of Tests
  • Pregnancy
  • Prospective Studies
  • Proto-Oncogene Proteins c-met / blood*
  • Risk Factors


  • Proto-Oncogene Proteins c-met